2025 H2 -tulosraportti
111 päivää sitten
‧38 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 796 | - | - | ||
| 1 864 | - | - | ||
| 10 280 | - | - | ||
| 340 | - | - | ||
| 8 635 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·7 t sittenA little fundamental perspective on Thor, since the share price has been weak lately, and since we have new invetorer who are not fully updated on cases. As I see it now, today's share price is mainly about one thing: the market is still waiting for proof that alphaone actually enters stable production. The positive thing is that the factory is now mechanically completed, the plant is in the commissioning phase, and the company still guides production start in Q3. The pilot plant has already produced and delivered samples to customers, so this is no longer just a powerpoint story. The risk now lies more in upscaling and GMP/qualification. On the capacity side, the numbers are interesting. Alphaone is guided to approx 21 000 doses after three years of operation, with around 350 million in annual revenue potential. Further upscaling of alphaone is communicated to approx 35 000 doses after five years and around 60 000 doses after ten years. (https://live.euronext.com/en/products/equities/company-news/2025-12-23-thor-medical-reaches-key-construction-milestones-alphaone) If one uses a 50 % EBITDA margin, one gets approximately: 21 000 doses / 350 MNOK revenue: EBITDA approx. 175 MNOK With EV/EBITDA 15–20x: Value approx 2,6–3,5 billion NOK Corresponds to approx 7–10 NOK per share 35 000 doses / 550 MNOK revenue: EBITDA approx 275 MNOK With EV/EBITDA 15–20x: Value approx 4,1–5,5 billion NOK Corresponds to approx 11–15 NOK per share 60 000 doses: If one assumes the same price level, we are quickly talking about close to 900–1 000 MNOK in annual revenue. With a 50 % EBITDA margin, that gives 450–500 MNOK EBITDA. With EV/EBITDA 15–20x: Value approx 6,8–10 billion NOK Corresponds to approx 19–28 NOK per share This is only AlphaOne. AlphaTwo is almost not factored in. AlphaTwo is referred to as a 10x capacity increase, but it is further in the future and may require financing. I therefore don't think the market is pricing in AlphaTwo to any significant extent now. Another underestimated factor is a carried forward loss of 3,06 billion. Thor has significant tax loss carryforwards. If the company becomes profitable, this can result in lower taxes for many years and thus higher free cash flow. In a pure EV/EBITDA model, this is not included, but in practice, the tax position could be worth around 1–2 NOK per share when the company starts making money. At the same time, one must be honest about the risk. This is still not a company with established commercial operations. The most important thing the market is waiting for now is not yet another small agreement, but confirmation that AlphaOne enters production, delivers GMP quality, and starts invoicing customers. As I see it: Bear case: Delay or technical/GMP problems can send the share price well down to the 3-range. Base case: AlphaOne starts production in Q3 and ramps up gradually. Then today's market value of around 1,4–1,5 billion NOK seems low compared to potential EBITDA. Bull case: AlphaOne works, capacity is filled, and the market starts pricing in 35k–60k doses and eventually AlphaTwo. Then, in my opinion, today's share price level is far from a realistic long-term potential.
·4 t sittenGood word again, I only trade Penny stocks because I think it's fun to hit one that suddenly becomes big, have also hit wrong many times, but that's the premise, what I mean with the Thor stock is that it's so flat, and many react to very small rises and falls. That was all. Have a good stock day😀
·10 t sittenAnyone have a thought about the price potential for this stock in the long term, like 2-5 years? If things go according to plan going forward. I myself have great faith in this stock and am thinking long-term!:)
·1 päivä sittenDr. Alf Bjørseth is a doyen in Norwegian industry, he is Commander of the Order of St. Olav.. Now he is 84 years old and must be allowed to retire. Capable man.
·1 päivä sittenProbably just retarded algorithms by some idiot with too much money creating all this chaos today. If we hadn't had this cancer on the Oslo Stock Exchange, it would have been a completely different market!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
111 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·7 t sittenA little fundamental perspective on Thor, since the share price has been weak lately, and since we have new invetorer who are not fully updated on cases. As I see it now, today's share price is mainly about one thing: the market is still waiting for proof that alphaone actually enters stable production. The positive thing is that the factory is now mechanically completed, the plant is in the commissioning phase, and the company still guides production start in Q3. The pilot plant has already produced and delivered samples to customers, so this is no longer just a powerpoint story. The risk now lies more in upscaling and GMP/qualification. On the capacity side, the numbers are interesting. Alphaone is guided to approx 21 000 doses after three years of operation, with around 350 million in annual revenue potential. Further upscaling of alphaone is communicated to approx 35 000 doses after five years and around 60 000 doses after ten years. (https://live.euronext.com/en/products/equities/company-news/2025-12-23-thor-medical-reaches-key-construction-milestones-alphaone) If one uses a 50 % EBITDA margin, one gets approximately: 21 000 doses / 350 MNOK revenue: EBITDA approx. 175 MNOK With EV/EBITDA 15–20x: Value approx 2,6–3,5 billion NOK Corresponds to approx 7–10 NOK per share 35 000 doses / 550 MNOK revenue: EBITDA approx 275 MNOK With EV/EBITDA 15–20x: Value approx 4,1–5,5 billion NOK Corresponds to approx 11–15 NOK per share 60 000 doses: If one assumes the same price level, we are quickly talking about close to 900–1 000 MNOK in annual revenue. With a 50 % EBITDA margin, that gives 450–500 MNOK EBITDA. With EV/EBITDA 15–20x: Value approx 6,8–10 billion NOK Corresponds to approx 19–28 NOK per share This is only AlphaOne. AlphaTwo is almost not factored in. AlphaTwo is referred to as a 10x capacity increase, but it is further in the future and may require financing. I therefore don't think the market is pricing in AlphaTwo to any significant extent now. Another underestimated factor is a carried forward loss of 3,06 billion. Thor has significant tax loss carryforwards. If the company becomes profitable, this can result in lower taxes for many years and thus higher free cash flow. In a pure EV/EBITDA model, this is not included, but in practice, the tax position could be worth around 1–2 NOK per share when the company starts making money. At the same time, one must be honest about the risk. This is still not a company with established commercial operations. The most important thing the market is waiting for now is not yet another small agreement, but confirmation that AlphaOne enters production, delivers GMP quality, and starts invoicing customers. As I see it: Bear case: Delay or technical/GMP problems can send the share price well down to the 3-range. Base case: AlphaOne starts production in Q3 and ramps up gradually. Then today's market value of around 1,4–1,5 billion NOK seems low compared to potential EBITDA. Bull case: AlphaOne works, capacity is filled, and the market starts pricing in 35k–60k doses and eventually AlphaTwo. Then, in my opinion, today's share price level is far from a realistic long-term potential.·4 t sittenGood word again, I only trade Penny stocks because I think it's fun to hit one that suddenly becomes big, have also hit wrong many times, but that's the premise, what I mean with the Thor stock is that it's so flat, and many react to very small rises and falls. That was all. Have a good stock day😀
- ·10 t sittenAnyone have a thought about the price potential for this stock in the long term, like 2-5 years? If things go according to plan going forward. I myself have great faith in this stock and am thinking long-term!:)
- ·1 päivä sittenDr. Alf Bjørseth is a doyen in Norwegian industry, he is Commander of the Order of St. Olav.. Now he is 84 years old and must be allowed to retire. Capable man.·1 päivä sittenProbably just retarded algorithms by some idiot with too much money creating all this chaos today. If we hadn't had this cancer on the Oslo Stock Exchange, it would have been a completely different market!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 796 | - | - | ||
| 1 864 | - | - | ||
| 10 280 | - | - | ||
| 340 | - | - | ||
| 8 635 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
111 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·7 t sittenA little fundamental perspective on Thor, since the share price has been weak lately, and since we have new invetorer who are not fully updated on cases. As I see it now, today's share price is mainly about one thing: the market is still waiting for proof that alphaone actually enters stable production. The positive thing is that the factory is now mechanically completed, the plant is in the commissioning phase, and the company still guides production start in Q3. The pilot plant has already produced and delivered samples to customers, so this is no longer just a powerpoint story. The risk now lies more in upscaling and GMP/qualification. On the capacity side, the numbers are interesting. Alphaone is guided to approx 21 000 doses after three years of operation, with around 350 million in annual revenue potential. Further upscaling of alphaone is communicated to approx 35 000 doses after five years and around 60 000 doses after ten years. (https://live.euronext.com/en/products/equities/company-news/2025-12-23-thor-medical-reaches-key-construction-milestones-alphaone) If one uses a 50 % EBITDA margin, one gets approximately: 21 000 doses / 350 MNOK revenue: EBITDA approx. 175 MNOK With EV/EBITDA 15–20x: Value approx 2,6–3,5 billion NOK Corresponds to approx 7–10 NOK per share 35 000 doses / 550 MNOK revenue: EBITDA approx 275 MNOK With EV/EBITDA 15–20x: Value approx 4,1–5,5 billion NOK Corresponds to approx 11–15 NOK per share 60 000 doses: If one assumes the same price level, we are quickly talking about close to 900–1 000 MNOK in annual revenue. With a 50 % EBITDA margin, that gives 450–500 MNOK EBITDA. With EV/EBITDA 15–20x: Value approx 6,8–10 billion NOK Corresponds to approx 19–28 NOK per share This is only AlphaOne. AlphaTwo is almost not factored in. AlphaTwo is referred to as a 10x capacity increase, but it is further in the future and may require financing. I therefore don't think the market is pricing in AlphaTwo to any significant extent now. Another underestimated factor is a carried forward loss of 3,06 billion. Thor has significant tax loss carryforwards. If the company becomes profitable, this can result in lower taxes for many years and thus higher free cash flow. In a pure EV/EBITDA model, this is not included, but in practice, the tax position could be worth around 1–2 NOK per share when the company starts making money. At the same time, one must be honest about the risk. This is still not a company with established commercial operations. The most important thing the market is waiting for now is not yet another small agreement, but confirmation that AlphaOne enters production, delivers GMP quality, and starts invoicing customers. As I see it: Bear case: Delay or technical/GMP problems can send the share price well down to the 3-range. Base case: AlphaOne starts production in Q3 and ramps up gradually. Then today's market value of around 1,4–1,5 billion NOK seems low compared to potential EBITDA. Bull case: AlphaOne works, capacity is filled, and the market starts pricing in 35k–60k doses and eventually AlphaTwo. Then, in my opinion, today's share price level is far from a realistic long-term potential.·4 t sittenGood word again, I only trade Penny stocks because I think it's fun to hit one that suddenly becomes big, have also hit wrong many times, but that's the premise, what I mean with the Thor stock is that it's so flat, and many react to very small rises and falls. That was all. Have a good stock day😀
- ·10 t sittenAnyone have a thought about the price potential for this stock in the long term, like 2-5 years? If things go according to plan going forward. I myself have great faith in this stock and am thinking long-term!:)
- ·1 päivä sittenDr. Alf Bjørseth is a doyen in Norwegian industry, he is Commander of the Order of St. Olav.. Now he is 84 years old and must be allowed to retire. Capable man.·1 päivä sittenProbably just retarded algorithms by some idiot with too much money creating all this chaos today. If we hadn't had this cancer on the Oslo Stock Exchange, it would have been a completely different market!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 796 | - | - | ||
| 1 864 | - | - | ||
| 10 280 | - | - | ||
| 340 | - | - | ||
| 8 635 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt